Dana-Farber News
@danafarbernews
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: [email protected]
ID: 989587598950785025
https://www.dana-farber.org/newsroom/ 26-04-2018 19:30:44
2,2K Tweet
5,5K Followers
406 Following
Encouraging anti-tumor activity for patients w/metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGFβ inhibitor BCA101 w/pembrolizumab. Dose expansion results reported by Dana-Farber's Glenn Hanna, MD, (Glenn J. Hanna, M.D.) at #ASCO23.